1. Home
  2. XIN vs APRE Comparison

XIN vs APRE Comparison

Compare XIN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XIN
  • APRE
  • Stock Information
  • Founded
  • XIN 1997
  • APRE 2006
  • Country
  • XIN China
  • APRE United States
  • Employees
  • XIN N/A
  • APRE N/A
  • Industry
  • XIN Homebuilding
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • XIN Consumer Discretionary
  • APRE Health Care
  • Exchange
  • XIN Nasdaq
  • APRE Nasdaq
  • Market Cap
  • XIN 15.9M
  • APRE 15.8M
  • IPO Year
  • XIN N/A
  • APRE 2019
  • Fundamental
  • Price
  • XIN $2.82
  • APRE $3.85
  • Analyst Decision
  • XIN
  • APRE Strong Buy
  • Analyst Count
  • XIN 0
  • APRE 2
  • Target Price
  • XIN N/A
  • APRE $15.50
  • AVG Volume (30 Days)
  • XIN 21.5K
  • APRE 33.0K
  • Earning Date
  • XIN 01-01-0001
  • APRE 11-07-2024
  • Dividend Yield
  • XIN N/A
  • APRE N/A
  • EPS Growth
  • XIN N/A
  • APRE N/A
  • EPS
  • XIN N/A
  • APRE N/A
  • Revenue
  • XIN $667,143,185.00
  • APRE $1,310,839.00
  • Revenue This Year
  • XIN N/A
  • APRE $134.21
  • Revenue Next Year
  • XIN N/A
  • APRE N/A
  • P/E Ratio
  • XIN $0.32
  • APRE N/A
  • Revenue Growth
  • XIN N/A
  • APRE 130.31
  • 52 Week Low
  • XIN $2.24
  • APRE $2.15
  • 52 Week High
  • XIN $7.05
  • APRE $8.85
  • Technical
  • Relative Strength Index (RSI)
  • XIN 50.53
  • APRE 56.63
  • Support Level
  • XIN $2.53
  • APRE $3.34
  • Resistance Level
  • XIN $2.86
  • APRE $3.83
  • Average True Range (ATR)
  • XIN 0.24
  • APRE 0.42
  • MACD
  • XIN 0.04
  • APRE 0.01
  • Stochastic Oscillator
  • XIN 69.35
  • APRE 36.04

About XIN Xinyuan Real Estate Co Ltd

Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Share on Social Networks: